Marilyn A Huestis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8204222/publications.pdf

Version: 2024-02-01

214 papers	12,106 citations	22153 59 h-index	37204 96 g-index
219 all docs	219 docs citations	219 times ranked	7592 citing authors

#	Article	IF	Citations
1	Combined effect of alcohol and cannabis on simulated driving. Psychopharmacology, 2022, 239, 1263-1277.	3.1	15
2	Identification of â^†9-tetrahydrocannabinol (THC) impairment using functional brain imaging. Neuropsychopharmacology, 2022, 47, 944-952.	5.4	10
3	Urinary clearance of 11â€norâ€9â€carboxyâ€Î”‹⁹â€tetrahydrocannabinol: A detailed pharmacokinetic analysis. Drug Testing and Analysis, 2022, 14, 1368-1376.	2.6	3
4	Substance use onset in high-risk 9â€“13Âyear-olds in the ABCD study. Neurotoxicology and Teratology, 2022, 91, 107090.	2.4	6
5	Separate and combined effects of alcohol and cannabis on mood, subjective experience, cognition and psychomotor performance: A randomized trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 118, 110570.	4.8	6
6	Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use. Drug Testing and Analysis, 2021, 13, 539-549.	2.6	18
7	A Review of Synthetic Cathinoneâ€“Related Fatalities From 2017 to 2020. Therapeutic Drug Monitoring, 2021, 43, 52-68.	2.0	44
8	Preliminary Evidence for Cannabis and Nicotine Urinary Metabolites as Predictors of Verbal Memory Performance and Learning Among Young Adults. Journal of the International Neuropsychological Society, 2021, 27, 546-558.	1.8	7
9	Prevalence of new psychoactive substances (NPS) in Brazil based on oral fluid analysis of samples collected at electronic music festivals and parties. Drug and Alcohol Dependence, 2021, 227, 108962.	3.2	17
10	Pyrrolidinyl Synthetic Cathinones Î±-PHP and 4F-Î±-PVP Metabolite Profiling Using Human Hepatocyte Incubations. International Journal of Molecular Sciences, 2021, 22, 230.	4.1	9
11	THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of â€œlight cannabisâ€• Clinical Chemistry and Laboratory Medicine, 2020, 58, 682-689.	2.3	40
12	Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath. Clinical Chemistry and Laboratory Medicine, 2020, 58, 673-681.	2.3	28
13	Monitoring Perinatal Exposure to Cannabis and Synthetic Cannabinoids. Therapeutic Drug Monitoring, 2020, 42, 194-204.	2.0	19
14	Testing Unconventional Matrices to Monitor for Prenatal Exposure to Heroin, Cocaine, Amphetamines, Synthetic Cathinones, and Synthetic Opioids. Therapeutic Drug Monitoring, 2020, 42, 205-221.	2.0	15
15	Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. Pharmacology Biochemistry and Behavior, 2020, 199, 173059.	2.9	28
16	Impact of cannabis and low alcohol concentration on divided attention tasks during driving. Traffic Injury Prevention, 2020, 21, S123-S129.	1.4	8
17	Screening of 104 New Psychoactive Substances (NPS) and Other Drugs of Abuse in Oral Fluid by LCâ€“MS-MS. Journal of Analytical Toxicology, 2020, 44, 697-707.	2.8	43
18	The effect of prenatal adversity on externalizing behaviors at 24 months of age in a highâ€risk sample: Maternal sensitivity as a moderator. Infant Mental Health Journal, 2020, 41, 530-542.	1.8	2

#	Article	IF	Citations
19	Toxicology and Analysis of Psychoactive Tryptamines. International Journal of Molecular Sciences, 2020, 21, 9279.	4.1	29
20	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug and Alcohol Dependence, 2020, 212, 107993.	3.2	49
21	Comparative Pharmacokinetics of Î”⁹-Tetrahydrocannabinol in Adolescent and Adult Male Mice. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 151-160.	2.5	56
22	Acute and residual mood and cognitive performance of young adults following smoked cannabis. Pharmacology Biochemistry and Behavior, 2020, 194, 172937.	2.9	18
23	Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users. Journal of Analytical Toxicology, 2020, 44, 651-660.	2.8	12
24	Prenatal Tobacco and Cannabis Exposure: Associations with Cortisol Reactivity in Early School Age Children. International Journal of Behavioral Medicine, 2020, 27, 343-356.	1.7	18
25	Subtherapeutic Acetazolamide Doses as a Noninvasive Method for Assessing Medication Adherence. Clinical Pharmacology and Therapeutics, 2020, 108, 1203-1212.	4.7	5
26	Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. Clinical Chemistry, 2020, 66, 888-914.	3.2	41
27	Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. Translational Psychiatry, 2020, 10, 71.	4.8	48
28	Prenatal tobacco and marijuana co-use: Sex-specific influences on infant cortisol stress response. Neurotoxicology and Teratology, 2020, 79, 106882.	2.4	9
29	Miniaturized extraction method for analysis of synthetic opioids in urine by microextraction with packed sorbent and liquid chromatographyâ€"tandem mass spectrometry. Journal of Chromatography A, 2020, 1624, 461241.	3.7	20
30	Oral Fluid Drug Testing: Analytical Approaches, Issues and Interpretation of Results. Journal of Analytical Toxicology, 2019, 43, 415-443.	2.8	78
31	Acute and residual effects of smoked cannabis: Impact on driving speed and lateral control, heart rate, and self-reported drug effects. Drug and Alcohol Dependence, 2019, 205, 107641.	3.2	44
32	Prenatal exposure to tobacco and marijuana and child autonomic regulation and reactivity: An analysis of indirect pathways via maternal psychopathology and parenting. Developmental Psychobiology, 2019, 61, 1022-1034.	1.6	9
33	Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. Journal of Psychoactive Drugs, 2019, 51, 108-117.	1.7	13
34	New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites. Frontiers in Chemistry, 2019, 7, 109.	3.6	95
35	Correlation of creatinineâ€•and specific gravityâ€•normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users. Drug Testing and Analysis, 2019, 11, 968-975.	2.6	17
36	Measuring Within-Individual Cannabis Reduction in Clinical Trials: a Review of the Methodological Challenges. Current Addiction Reports, 2019, 6, 429-436.	3.4	9

#	Article	IF	Citations
37	Cannabidiol Adverse Effects and Toxicity. Current Neuropharmacology, 2019, 17, 974-989.	2.9	244
38	Cannabinoid Markers in Biological Fluids and Tissues: Revealing Intake. Trends in Molecular Medicine, 2018, 24, 156-172.	6.7	47
39	Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicology, 2018, 36, 304-312.	2.4	10
40	Drug exposure during pregnancy: analytical methods and toxicological findings. Bioanalysis, 2018, 10, 587-606.	1.5	28
41	Prenatal Risk and Infant Regulation: Indirect Pathways via Fetal Growth and Maternal Prenatal Stress and Anger. Child Development, 2018, 89, e123-e137.	3.0	15
42	Optimization of recombinant Î²â€glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry. Drug Testing and Analysis, 2018, 10, 518-529.	2.6	22
43	Quantification of ethyl glucuronide, ethyl sulfate, nicotine, and its metabolites in human fetal liver and placenta. Forensic Toxicology, 2018, 36, 102-112.	2.4	6
44	Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 543-550.	2.5	17
45	Prenatal tobacco and marijuana co-use: Impact on newborn neurobehavior. Neurotoxicology and Teratology, 2018, 70, 28-39.	2.4	19
46	Prenatal exposure to tobacco and cannabis: Effects on autonomic and emotion regulation. Neurotoxicology and Teratology, 2018, 68, 47-56.	2.4	27
47	Additive drug-specific and sex-specific risks associated with co-use of marijuana and tobacco during pregnancy: Evidence from 3 recent developmental cohorts (2003â€“2015). Neurotoxicology and Teratology, 2018, 68, 97-106.	2.4	19
48	Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. Journal of Pharmaceutical and Biomedical Analysis, 2018, 157, 27-35.	2.8	21
49	Co-use of tobacco and marijuana during pregnancy: Pathways to externalizing behavior problems in early childhood. Neurotoxicology and Teratology, 2018, 69, 39-48.	2.4	11
50	Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS ONE, 2018, 13, e0190768.	2.5	88
51	In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicology, 2017, 35, 20-32.	2.4	31
52	Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration. Journal of Applied Toxicology, 2017, 37, 922-932.	2.8	29
53	Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes. AAPS Journal, 2017, 19, 568-577.	4.4	25
54	Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Î”9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration. Clinical Chemistry, 2017, 63, 647-662.	3.2	44

#	Article	IF	Citations
55	Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. Drug and Alcohol Dependence, 2017, 175, 67-76.	3.2	65
56	Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013â€“2016: A Review. Journal of Analytical Toxicology, 2017, 41, 573-610.	2.8	128
57	On-site oral fluid Î”9-tetrahydrocannabinol (THC) screening after controlled smoked, vaporized, and oral cannabis administration. Forensic Toxicology, 2017, 35, 133-145.	2.4	13
58	Modelling foetal exposure to maternal smoking using hepatoblasts from pluripotent stem cells. Archives of Toxicology, 2017, 91, 3633-3643.	4.2	22
59	Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry. Clinical Chemistry, 2017, 63, 1008-1021.	3.2	48
60	In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicology, 2017, 35, 252-262.	2.4	7
61	Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18. Clinical Chemistry, 2017, 63, 1753-1763.	3.2	11
62	Changes in marijuana use symptoms and emotional functioning over 28-days of monitored abstinence in adolescent marijuana users. Psychopharmacology, 2017, 234, 3431-3442.	3.1	23
63	Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. Drug and Alcohol Dependence, 2017, 180, 68-75.	3.2	34
64	Smoking in Pregnancy and Fetal Growth: The Case for More Intensive Assessment. Nicotine and Tobacco Research, 2017, 19, 525-531.	2.6	28
65	Impact of Novel Psychoactive Substances on Clinical and Forensic Toxicology and Global Public Health. Clinical Chemistry, 2017, 63, 1564-1569.	3.2	31
66	25Câ€NBOMe and 25Iâ€NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with highâ€resolution mass spectrometry. Drug Testing and Analysis, 2017, 9, 680-698.	2.6	43
67	Longâ€term stability of cannabinoids in oral fluid after controlled cannabis administration. Drug Testing and Analysis, 2017, 9, 143-147.	2.6	27
68	Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker Metabolites. Clinical Pharmacology and Therapeutics, 2017, 101, 239-253.	4.7	81
69	Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. Drug Testing and Analysis, 2017, 9, 905-915.	2.6	80
70	In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. Current Neuropharmacology, 2017, 15, 682-691.	2.9	39
71	Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake. Clinical Chemistry, 2016, 62, 1579-1592.	3.2	139
72	A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. Journal of Pain Research, 2016, Volume 9, 587-598.	2.0	38

#	Article	IF	Citations
73	Metabolic characterization of AHâ€7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation. Drug Testing and Analysis, 2016, 8, 779-791.	2.6	33
74	Cannabis effects on driving longitudinal control with and without alcohol. Journal of Applied Toxicology, 2016, 36, 1418-1429.	2.8	77
75	Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluidâ€blood cannabinoid relationships. Drug Testing and Analysis, 2016, 8, 690-701.	2.6	38
76	Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. Forensic Toxicology, 2016, 34, 256-267.	2.4	21
77	First metabolic profile of PV8, a novel synthetic cathinone, in human hepatocytes and urine by high-resolution mass spectrometry. Analytical and Bioanalytical Chemistry, 2016, 408, 4845-4856.	3.7	34
78	Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration. Drug and Alcohol Dependence, 2016, 163, 116-125.	3.2	18
79	Drug Recognition Expert (DRE) examination characteristics of cannabis impairment. Accident Analysis and Prevention, 2016, 92, 219-229.	5.7	49
80	Tobacco exposure and maternal psychopathology: Impact on toddler problem behavior. Neurotoxicology and Teratology, 2016, 57, 87-94.	2.4	9
81	Adolescent cortical thickness pre- and post marijuana and alcohol initiation. Neurotoxicology and Teratology, 2016, 57, 20-29.	2.4	43
82	Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry. AAPS Journal, 2016, 18, 1489-1499.	4.4	69
83	Epigenetic Regulation of Placental NR3C1: Mechanism Underlying Prenatal Programming of Infant Neurobehavior by Maternal Smoking?. Child Development, 2016, 87, 49-60.	3.0	43
84	Maternal Buprenorphine Maintenance and Lactation. Journal of Human Lactation, 2016, 32, 675-681.	1.6	31
85	Effects of fetal tobacco exposure on focused attention in infancy. , 2016, 45, 1-10.		7
86	Cannabinoids Pharmacology, Abuse, and Addiction. , 2016, , 1-27.		0
87	Simultaneous quantification of 11 cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX-S tips. Analytical and Bioanalytical Chemistry, 2016, 408, 6461-6471.	3.7	49
88	Reprint of â€œAdolescent cortical thickness pre- and post marijuana and alcohol initiationâ€. Neurotoxicology and Teratology, 2016, 58, 78-87.	2.4	1
89	Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs. Current Topics in Behavioral Neurosciences, 2016, 32, 93-117.	1.7	113
90	Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases. Drug Metabolism Reviews, 2016, 48, 237-265.	3.6	60

#	Article	IF	Citations
91	Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A, 2016, 1451, 97-106.	3.7	6
92	Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry. Journal of Chromatography A, 2016, 1453, 34-42.	3.7	48
93	Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance. Drug Testing and Analysis, 2016, 8, 682-689.	2.6	33
94	Metabolic profiling of new synthetic cannabinoids AMB and 5Fâ€AMB by human hepatocyte and liver microsome incubations and highâ€resolution mass spectrometry. Rapid Communications in Mass Spectrometry, 2016, 30, 1067-1078.	1.5	56
95	Linear pharmacokinetics of 3,4â€methylenedioxypyrovalerone (<scp>MDPV</scp>) and its metabolites in the rat: relationship to pharmacodynamic effects. Addiction Biology, 2016, 21, 339-347.	2.6	83
96	Effect of Blood Collection Time on Measured Î”9-Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy. Clinical Chemistry, 2016, 62, 367-377.	3.2	51
97	Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. Forensic Science International, 2016, 260, 95-101.	2.2	23
98	In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22. AAPS Journal, 2016, 18, 455-464.	4.4	50
99	In vitro, in vivo and in silico metabolic profiling of Î±-pyrrolidinopentiothiophenone, a novel thiophene stimulant. Bioanalysis, 2016, 8, 65-82.	1.5	44
100	High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes. Clinical Chemistry, 2016, 62, 157-169.	3.2	65
101	4-Methoxy-Î±-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry. Forensic Toxicology, 2016, 34, 61-75.	2.4	46
102	Comparison of (+)- and (-)-Naloxone on the Acute Psychomotor-Stimulating Effects of Heroin, 6-Acetylmorphine, and Morphine in Mice. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 209-215.	2.5	3
103	In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. Current Neuropharmacology, 2016, , .	2.9	1
104	Prenatal tobacco exposure and infant stress reactivity: Role of child sex and maternal behavior. Developmental Psychobiology, 2015, 57, 212-225.	1.6	21
105	Urine Mescaline Screening With a Biochip Array Immunoassay and Quantification by Gas Chromatographyâ€“Mass Spectrometry. Therapeutic Drug Monitoring, 2015, 37, 805-811.	2.0	5
106	Validation of an ELISA Synthetic Cannabinoids Urine Assay. Therapeutic Drug Monitoring, 2015, 37, 661-669.	2.0	20
107	Smoked Cannabis' Psychomotor and Neurocognitive Effects in Occasional and Frequent Smokers. Journal of Analytical Toxicology, 2015, 39, 251-261.	2.8	106
108	Biochip array technology immunoassay performance and quantitative confirmation of designer piperazines for urine workplace drug testing. Analytical and Bioanalytical Chemistry, 2015, 407, 4639-4648.	3.7	20

#	Article	IF	Citations
109	Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. Clinical Chemistry, 2015, 61, 850-869.	3.2	119
110	Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens. Clinical Chemistry and Laboratory Medicine, 2015, 53, 423-34.	2.3	28
111	Cannabis-Impaired Driving: A Public Health and Safety Concern. Clinical Chemistry, 2015, 61, 1223-1225.	3.2	17
112	Impact of oral fluid collection device on cannabinoid stability following smoked cannabis. Drug Testing and Analysis, 2015, 7, 114-120.	2.6	22
113	Quantification of methylone and metabolites in rat and human plasma by liquid chromatography-tandem mass spectrometry. Forensic Toxicology, 2015, 33, 202-212.	2.4	9
114	The Corticotropin Releasing Hormone-1 (CRH1) Receptor Antagonist Pexacerfont in Alcohol Dependence: A Randomized Controlled Experimental Medicine Study. Neuropsychopharmacology, 2015, 40, 1053-1063.	5.4	127
115	Cannabis effects on driving lateral control with and without alcohol. Drug and Alcohol Dependence, 2015, 154, 25-37.	3.2	182
116	Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatographyâ€“high resolution mass spectrometry and library matching. Journal of Chromatography A, 2015, 1397, 32-42.	3.7	103
117	Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug Metabolism Reviews, 2015, 47, 124-174.	3.6	91
118	Cannabinoid disposition in oral fluid after controlled vaporizer administration with and without alcohol. Forensic Toxicology, 2015, 33, 260-278.	2.4	14
119	Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry. Forensic Toxicology, 2015, 33, 295-310.	2.4	58
120	Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA. AAPS Journal, 2015, 17, 660-677.	4.4	94
121	Plasma Cannabinoid Pharmacokinetics After Controlled Smoking andAd libitumCannabis Smoking in Chronic Frequent Users. Journal of Analytical Toxicology, 2015, 39, 580-587.	2.8	40
122	Cocaine and metabolite concentrations in DBS and venous blood after controlled intravenous cocaine administration. Bioanalysis, 2015, 7, 2041-2056.	1.5	24
123	Quantification of six cannabinoids and metabolites in oral fluid by liquid chromatographyâ€tandem mass spectrometry. Drug Testing and Analysis, 2015, 7, 684-694.	2.6	45
124	Highâ€resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, Nâ€(adamantanâ€1â€yl)â€1â€(5â€fluoropentyl)â€1Hâ€indoleâ€3â€carboxamide (STSâ€135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. Drug Testing and Analysis, 2015, 7, 187-198.	2.6	40
125	Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. Drug Testing and Analysis, 2015, 7, 483-493.	2.6	35
126	Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids. Drug Testing and Analysis, 2015, 7, 467-474.	2.6	29

#	Article	IF	Citations
127	Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2015, 407, 883-897.	3.7	116
128	Quantification of cocaine and metabolites in exhaled breath by liquid chromatography-high-resolution mass spectrometry following controlled administration of intravenous cocaine. Analytical and Bioanalytical Chemistry, 2014, 406, 6213-6223.	3.7	25
129	Method validation of the biochip array technology for synthetic cannabinoids detection in urine. Bioanalysis, 2014, 6, 2919-2930.	1.5	16
130	Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. Bioanalysis, 2014, 6, 1187-1200.	1.5	22
131	Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. Drug Testing and Analysis, 2014, 6, 1002-1010.	2.6	30
132	Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism andÂTOF-MS. Bioanalysis, 2014, 6, 1471-1485.	1.5	19
133	Quantification of 11-Nor-9-Carboxy-Î”9-Tetrahydrocannabinol in Human Oral Fluid by Gas Chromatographyâ€“Tandem Mass Spectrometry. Therapeutic Drug Monitoring, 2014, 36, 225-233.	2.0	14
134	Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence. Therapeutic Drug Monitoring, 2014, 36, 218-224.	2.0	17
135	Current knowledge on cannabinoids in oral fluid. Drug Testing and Analysis, 2014, 6, 88-111.	2.6	84
136	In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis. Analytical and Bioanalytical Chemistry, 2014, 406, 785-792.	3.7	25
137	Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Analytical and Bioanalytical Chemistry, 2014, 406, 1763-1780.	3.7	97
138	Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology. Drug Testing and Analysis, 2014, 6, 728-738.	2.6	54
139	3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatographyâ€“high resolution mass spectrometry. Analytica Chimica Acta, 2014, 827, 54-63.	5.4	40
140	Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine. Forensic Science International, 2014, 241, 27-34.	2.2	46
141	Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography A, 2014, 1327, 105-117.	3.7	92
142	Validation of a novel method to identify in utero ethanol exposure: simultaneous meconium extraction of fatty acid ethyl esters, ethyl glucuronide, and ethyl sulfate followed by LC-MS/MS quantification. Analytical and Bioanalytical Chemistry, 2014, 406, 1945-1955.	3.7	30
143	Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence, 2014, 144, 12-41.	3.2	572
144	Urinary Cannabinoid Disposition in Occasional and Frequent Smokers: Is THC-Glucuronide in Sequential Urine Samples a Marker of Recent Use in Frequent Smokers?. Clinical Chemistry, 2014, 60, 361-372.	3.2	38

#	Article	IF	Citations
145	The Potential Role of Oral Fluid in Antidoping Testing. Clinical Chemistry, 2014, 60, 307-322.	3.2	58
146	Phase I and II Cannabinoid Disposition in Blood and Plasma of Occasional and Frequent Smokers Following Controlled Smoked Cannabis. Clinical Chemistry, 2014, 60, 631-643.	3.2	127
147	Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices. Analytical and Bioanalytical Chemistry, 2014, 406, 4117-4128.	3.7	35
148	Maternal smoking during pregnancy and infant stress response: Test of a prenatal programming hypothesis. Psychoneuroendocrinology, 2014, 48, 29-40.	2.7	88
149	Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. Analytical and Bioanalytical Chemistry, 2013, 405, 7269-7279.	3.7	24
150	11-Nor-9-carboxy-âˆ†9-tetrahydrocannabinol quantification in human oral fluid by liquid chromatographyâ€“tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2013, 405, 6019-6027.	3.7	20
151	Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. Analytical and Bioanalytical Chemistry, 2013, 405, 4679-4689.	3.7	35
152	First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry. AAPS Journal, 2013, 15, 1091-1098.	4.4	75
153	Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry. Analytical and Bioanalytical Chemistry, 2013, 405, 9437-9448.	3.7	106
154	First Metabolic Profile of XLR-11, a Novel Synthetic Cannabinoid, Obtained by Using Human Hepatocytes and High-Resolution Mass Spectrometry. Clinical Chemistry, 2013, 59, 1638-1648.	3.2	82
155	Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers. Analytical and Bioanalytical Chemistry, 2013, 405, 8451-8461.	3.7	47
156	Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?. Drug and Alcohol Dependence, 2013, 130, 68-76.	3.2	29
157	Simultaneous quantification of Î”9-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol and cannabinol in oral fluid by microflow-liquid chromatographyâ€“high resolution mass spectrometry. Journal of Chromatography A, 2013, 1297, 123-130.	3.7	38
158	Cannabis Effects on Driving Skills. Clinical Chemistry, 2013, 59, 478-492.	3.2	476
159	Qualitative Confirmation of 9 Synthetic Cannabinoids and 20 Metabolites in Human Urine Using LCâ€“MS/MS and Library Search. Analytical Chemistry, 2013, 85, 3730-3738.	6.5	108
160	Impact of Prolonged Cannabinoid Excretion in Chronic Daily Cannabis Smokers' Blood on Per Se Drugged Driving Laws. Clinical Chemistry, 2013, 59, 519-526.	3.2	127
161	Changes in Smoking Patterns During Pregnancy. Substance Use and Misuse, 2013, 48, 513-522.	1.4	40
162	Identifying Methamphetamine Exposure in Children. Therapeutic Drug Monitoring, 2013, 35, 823-830.	2.0	15

#	Article	IF	Citations
163	Tolerance to Effects of High-Dose Oral Î”9-Tetrahydrocannabinol and Plasma Cannabinoid Concentrations in Male Daily Cannabis Smokers. Journal of Analytical Toxicology, 2013, 37, 11-16.	2.8	64
164	Cannabinoids in Exhaled Breath following Controlled Administration of Smoked Cannabis. Clinical Chemistry, 2013, 59, 1780-1789.	3.2	84
165	In Vitro Stability of Free and Glucuronidated Cannabinoids in Blood and Plasma Following Controlled Smoked Cannabis. Clinical Chemistry, 2013, 59, 1108-1117.	3.2	45
166	Cannabinoid Stability in Authentic Oral Fluid after Controlled Cannabis Smoking. Clinical Chemistry, 2012, 58, 1101-1109.	3.2	56
167	Cannabinoid Disposition in Oral Fluid after Controlled Smoked Cannabis. Clinical Chemistry, 2012, 58, 748-756.	3.2	59
168	On-Site Test for Cannabinoids in Oral Fluid. Clinical Chemistry, 2012, 58, 1418-1425.	3.2	44
169	Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis. Clinica Chimica Acta, 2012, 413, 765-770.	1.1	48
170	Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry. Clinica Chimica Acta, 2012, 413, 1839-1847.	1.1	57
171	Predictive model accuracy in estimating last Î”9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug and Alcohol Dependence, 2012, 125, 313-319.	3.2	41
172	Psychomotor Performance, Subjective and Physiological Effects and Whole Blood Â9-Tetrahydrocannabinol Concentrations in Heavy, Chronic Cannabis Smokers Following Acute Smoked Cannabis. Journal of Analytical Toxicology, 2012, 36, 405-412.	2.8	84
173	Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use endâ€points in clinical trials. Addiction, 2012, 107, 694-708.	3.3	184
174	Piezoresistive Microcantilevers-Based Cocaine Biosensors. Sensor Letters, 2012, 10, 850-855.	0.4	12
175	Plasma Cannabinoid Pharmacokinetics following Controlled Oral Î”9-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration. Clinical Chemistry, 2011, 57, 66-75.	3.2	189
176	Cannabis in Sport. Sports Medicine, 2011, 41, 949-966.	6.5	64
177	Anger, Hostility, and Aggression as Predictors of Persistent Smoking During Pregnancy. Journal of Studies on Alcohol and Drugs, 2011, 72, 926-932.	1.0	35
178	Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction, 2011, 106, 499-506.	3.3	68
179	Postmortem redistribution of Î”9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Forensic Science International, 2011, 212, 247-251.	2.2	40
180	Cannabinoids and metabolites in expectorated oral fluid after 8Âdays of controlled around-the-clock oral THC administration. Analytical and Bioanalytical Chemistry, 2011, 401, 599-607.	3.7	27

#	Article	IF	Citations
181	Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatographyâ€“tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2011, 401, 1273-1283.	3.7	91
182	Development and validation of LCâ€HRMS and GCâ€NICIâ€MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine. Journal of Mass Spectrometry, 2011, 46, 603-614.	1.6	30
183	Identification of Recent Cannabis Use: Whole-Blood and Plasma Free and Glucuronidated Cannabinoid Pharmacokinetics following Controlled Smoked Cannabis Administration. Clinical Chemistry, 2011, 57, 1406-1414.	3.2	149
184	Oral Fluid and Plasma Cannabinoid Ratios after Around-the-Clock Controlled Oral Î”9-Tetrahydrocannabinol Administration. Clinical Chemistry, 2011, 57, 1597-1606.	3.2	33
185	Pharmacokinetics of Cocaine and Metabolites in Human Oral Fluid and Correlation With Plasma Concentrations After Controlled Administration. Therapeutic Drug Monitoring, 2010, 32, 628-637.	2.0	70
186	Effect of hydrolysis on identifying prenatal cannabis exposure. Analytical and Bioanalytical Chemistry, 2010, 397, 2335-2347.	3.7	26
187	Identifying Prenatal Cannabis Exposure and Effects of Concurrent Tobacco Exposure on Neonatal Growth. Clinical Chemistry, 2010, 56, 1442-1450.	3.2	106
188	Disposition of Cannabinoids in Oral Fluid after Controlled Around-the-Clock Oral THC Administration. Clinical Chemistry, 2010, 56, 1261-1269.	3.2	43
189	Nicotine and metabolites in meconium as evidence of maternal cigarette smoking during pregnancy and predictors of neonatal growth deficits. Nicotine and Tobacco Research, 2010, 12, 658-664.	2.6	52
190	Simultaneous quantification of nicotine, opioids, cocaine, and metabolites in human fetal postmortem brain by liquid chromatography tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2009, 393, 1957-1965.	3.7	29
191	A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. Analytical and Bioanalytical Chemistry, 2009, 393, 1977-1990.	3.7	58
192	Do Î”⁹â€tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?. Addiction, 2009, 104, 2041-2048.	3.3	94
193	Identifying New Cannabis Use with Urine Creatinine-Normalized THCCOOH Concentrations and Time Intervals Between Specimen Collections. Journal of Analytical Toxicology, 2009, 33, 185-189.	2.8	62
194	Extended urinary Î”9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug and Alcohol Dependence, 2009, 105, 24-32.	3.2	99
195	Oral Fluid Testing for Drugs of Abuse. Clinical Chemistry, 2009, 55, 1910-1931.	3.2	340
196	Intra- and Intersubject Whole Blood/Plasma Cannabinoid Ratios Determined by 2-Dimensional, Electron Impact GC-MS with Cryofocusing. Clinical Chemistry, 2009, 55, 1188-1195.	3.2	53
197	Identification of Prenatal Amphetamines Exposure by Maternal Interview and Meconium Toxicology in the Infant Development, Environment and Lifestyle (IDEAL) Study. Therapeutic Drug Monitoring, 2009, 31, 769-775.	2.0	41
198	Excretion of Î”9-tetrahydrocannabinol in sweat. Forensic Science International, 2008, 174, 173-177.	2.2	52

#	Article	IF	Citations
199	Excretion of Methamphetamine and Amphetamine in Human Sweat Following Controlled Oral Methamphetamine Administration. Clinical Chemistry, 2008, 54, 172-180.	3.2	43
200	Urinary Elimination of 11-Nor-9-Carboxy-Â9-tetrahydrocannnabinol in Cannabis Users During Continuously Monitored Abstinence. Journal of Analytical Toxicology, 2008, 32, 562-569.	2.8	92
201	Meconium Nicotine and Metabolites by Liquid Chromatography-Tandem Mass Spectrometry: Differentiation of Passive and Nonexposure and Correlation with Neonatal Outcome Measures. Clinical Chemistry, 2008, 54, 2018-2027.	3.2	28
202	Simultaneous GC-EI-MS Determination of Â9-Tetrahydrocannabinol, 11-Hydroxy-Â9-Tetrahydrocannabinol, and 11-nor-9-Carboxy-Â9-Tetrahydrocannabinol in Human Urine Following Tandem Enzyme-Alkaline Hydrolysis. Journal of Analytical Toxicology, 2007, 31, 477-485.	2.8	75
203	Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology, 2007, 194, 505-515.	3.1	144
204	Cannabinoid concentrations in hair from documented cannabis users. Forensic Science International, 2007, 169, 129-136.	2.2	95
205	Estimating Time of Last Oral Ingestion of Cannabis From Plasma THC and THCCOOH Concentrations. Therapeutic Drug Monitoring, 2006, 28, 540-544.	2.0	40
206	Estimating the Time of Last Cannabis Use from Plasma Î”9-Tetrahydrocannabinol and 11-nor-9-Carboxy-Î”9-Tetrahydrocannabinol Concentrations. Clinical Chemistry, 2005, 51, 2289-2295.	3.2	76
207	Relationship of Â9-Tetrahydrocannabinol Concentrations in Oral Fluid and Plasma after Controlled Administration of Smoked Cannabis. Journal of Analytical Toxicology, 2004, 28, 394-399.	2.8	194
208	Urinary Cannabinoid Detection Times after Controlled Oral Administration of Î”9-Tetrahydrocannabinol to Humans. Clinical Chemistry, 2003, 49, 1114-1124.	3.2	37
209	A Rapid Reusable Fiber Optic Biosensor for Detecting Cocaine Metabolites in Urine. Journal of Analytical Toxicology, 1999, 23, 460-467.	2.8	28
210	Urinary Excretion Half-Life of 11-Nor-9-carboxy-Î”9-tetrahydrocannabinol in Humans. Therapeutic Drug Monitoring, 1998, 20, 570-576.	2.0	71
211	Relating Blood Concentrations of Tetrahydrocannabinol and Metabolites to Pharmacologic Effects and Time of Marijuana Usage. Therapeutic Drug Monitoring, 1993, 15, 527-532.	2.0	85
212	Blood Cannabinoids. II. Models for the Prediction of Time of Marijuana Exposure from Plasma Concentrations of Î”9-Tetrahydrocannabinol (THC) and 11-nor-9-carboxy-Î”9-tetrahydrocannabinol (THCCOOH). Journal of Analytical Toxicology, 1992, 16, 283-290.	2.8	131
213	Blood Cannabinoids. I. Absorption of THC and Formation of 11-OH-THC and THCCOOH During and After Smoking Marijuana*. Journal of Analytical Toxicology, 1992, 16, 276-282.	2.8	445
214	Acute and residual effects of marijuana: Profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacology Biochemistry and Behavior, 1990, 37, 561-565.	2.9	122